HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takuma Sasaki Selected Research

1- (3- C- ethynylribopentofuranosyl)cytosine

5/20091-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
1/2009Molecular mechanisms of apoptosis induced by 3'-ethynylcytidine.
6/2007Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil.
5/2005Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
7/2002Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.
4/2002Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106.
1/2002Anticancer mechanisms of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takuma Sasaki Research Topics

Disease

37Neoplasms (Cancer)
01/2022 - 09/2000
14Stomach Neoplasms (Stomach Cancer)
06/2018 - 09/2000
7Neoplasm Metastasis (Metastasis)
12/2005 - 09/2000
6Carcinoma (Carcinomatosis)
10/2010 - 04/2002
5Fibrosarcoma
10/2007 - 01/2002
3Ascites
10/2005 - 11/2002
3Neoplasm Micrometastasis
01/2004 - 11/2002
2Esophageal Squamous Cell Carcinoma
03/2022 - 01/2022
2Lymphatic Metastasis
01/2022 - 01/2003
2Pain (Aches)
01/2019 - 01/2019
2Virus Diseases (Viral Diseases)
11/2010 - 01/2007
2Lung Neoplasms (Lung Cancer)
05/2009 - 06/2006
2Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/2007 - 11/2002
2Adenocarcinoma
10/2003 - 01/2003
1Colic (Abdominal Cramps)
07/2021
1Cholecystitis
07/2021
1Low Back Pain (Lumbago)
01/2019
1Cancer Pain
01/2019
1Vomiting
06/2018
1Esophageal Neoplasms (Esophageal Cancer)
06/2018
1Esophageal Perforation
06/2018
1Fistula
06/2018
1Astrocytoma (Pilocytic Astrocytoma)
04/2007
1Glioblastoma (Glioblastoma Multiforme)
04/2007
1Squamous Cell Carcinoma of Head and Neck
12/2005
1Pancreatic Neoplasms (Pancreatic Cancer)
05/2005

Drug/Important Bio-Agent (IBA)

10NucleosidesIBA
10/2010 - 04/2002
9Proteins (Proteins, Gene)FDA Link
11/2010 - 09/2000
7Messenger RNA (mRNA)IBA
01/2022 - 09/2000
71- (3- C- ethynylribopentofuranosyl)cytosineIBA
05/2009 - 01/2002
6Fluorouracil (Carac)FDA LinkGeneric
06/2007 - 11/2002
4Docetaxel (Taxotere)FDA Link
06/2006 - 07/2004
32-5A-dependent ribonuclease (RNase L)IBA
11/2010 - 01/2006
3Cisplatin (Platino)FDA LinkGeneric
05/2009 - 06/2006
3CollagenIBA
04/2007 - 01/2005
3Carboplatin (JM8)FDA LinkGeneric
04/2007 - 10/2005
3GemcitabineFDA Link
06/2006 - 02/2004
3Pharmaceutical PreparationsIBA
02/2005 - 01/2003
3phosmidosineIBA
10/2004 - 05/2002
3EnzymesIBA
09/2004 - 09/2000
2Biomarkers (Surrogate Marker)IBA
03/2022 - 01/2022
2Oxycodone (Oxycontin)FDA LinkGeneric
01/2019 - 01/2019
2DNA-Directed RNA Polymerases (RNA Polymerase)IBA
05/2009 - 10/2004
2CytosineIBA
04/2009 - 01/2007
2Antineoplastic Agents (Antineoplastics)IBA
04/2007 - 05/2002
2titanium silicide (TS-1)IBA
01/2007 - 10/2005
2Thymidylate SynthaseIBA
06/2006 - 09/2004
2Amino AcidsFDA Link
01/2006 - 06/2003
2RNA (Ribonucleic Acid)IBA
01/2005 - 01/2002
2Peptides (Polypeptides)IBA
10/2004 - 07/2003
2Cytidine DeaminaseIBA
02/2004 - 01/2003
2Indicators and Reagents (Reagents)IBA
10/2003 - 09/2000
2Phosphotransferases (Kinase)IBA
06/2003 - 05/2003
1Sirtuin 1IBA
03/2022
1Heat-Shock Proteins (Heat-Shock Protein)IBA
01/2022
1Metformin (Glucophage)FDA LinkGeneric
01/2022
1Tumor Biomarkers (Tumor Markers)IBA
01/2022
1Hypoglycemic Agents (Hypoglycemics)IBA
01/2022
1Analgesics (Analgesic Drugs)IBA
01/2019
1Opioid Analgesics (Opioids)IBA
01/2019
1Delayed-Action PreparationsIBA
01/2019
1ras ProteinsIBA
11/2010
1RNA Polymerase I (Polymerase I, RNA)IBA
11/2010
1EndoribonucleasesIBA
11/2010
1Apoptosis Regulatory ProteinsIBA
11/2010
1Ribonucleases (Ribonuclease)IBA
11/2010
1N-(4-isothiocyanatophenethyl)spiperoneIBA
09/2009
1Green Fluorescent ProteinsIBA
10/2007
1NimustineIBA
04/2007
1Etoposide (VP 16)FDA LinkGeneric
04/2007
1soblidotin (TZT 1027)IBA
03/2007
1AntimetabolitesIBA
01/2007
13'-ethynyladenosineIBA
01/2007
1Capecitabine (Xeloda)FDA Link
01/2007
1Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA
01/2007
1Adenosine (Adenocard)FDA LinkGeneric
01/2007
1monoclonal antibody D2-40IBA
09/2006
1Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA
06/2006
1Proliferating Cell Nuclear Antigen (PCNA)IBA
06/2006
1PlatinumIBA
06/2006
1Irinotecan (Camptosar)FDA LinkGeneric
06/2006
1Cadherins (E-Cadherin)IBA
12/2005
1Vascular Endothelial Growth Factor CIBA
10/2005
1Vascular Endothelial Growth Factor DIBA
10/2005
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2005
1Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
10/2005
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2005

Therapy/Procedure

12Drug Therapy (Chemotherapy)
09/2009 - 11/2002
2Therapeutics
01/2004 - 07/2003
2Oral Administration
01/2004 - 11/2002
1Laparoscopic Cholecystectomy
07/2021
1Analgesia
01/2019
1Esophagectomy
06/2018
1Endoscopes
06/2018
1Chemoradiotherapy
06/2018
1Gastrectomy
06/2018
1Gastrostomy
06/2018
1Cytoreduction Surgical Procedures
09/2009
1Injections
10/2005
1Intraperitoneal Injections
02/2005